Literature DB >> 25377908

Guideline for the acquisition and preparation of conventional and endobronchial ultrasound-guided transbronchial needle aspiration specimens for the diagnosis and molecular testing of patients with known or suspected lung cancer.

Erik H F M van der Heijden1, Roberto F Casal, Rocco Trisolini, Daniel P Steinfort, Bin Hwangbo, Takahiro Nakajima, Birgit Guldhammer-Skov, Giulio Rossi, Maurizio Ferretti, Felix F J Herth, Rex Yung, Mark Krasnik.   

Abstract

RATIONALE: Conventional transbronchial needle aspiration (TBNA) and endobronchial ultrasound (EBUS)-TBNA are widely accepted tools for the diagnosis and staging of lung cancer and the initial procedure of choice for staging. Obtaining adequate specimens is key to provide a specific histologic and molecular diagnosis of lung cancer.
OBJECTIVES: To develop practice guidelines on the acquisition and preparation of conventional TBNA and EBUS-TBNA specimens for the diagnosis and molecular testing of (suspected) lung cancer. We hope to improve the global unification of procedure standards, maximize the yield and identify areas for research.
METHODS: Systematic electronic database searches were conducted to identify relevant studies for inclusion in the guideline [PubMed and the Cochrane Library (including the Cochrane Database of Systematic Reviews)]. MAIN
RESULTS: The number of needle aspirations with both conventional TBNA and EBUS-TBNA was found to impact the diagnostic yield, with at least 3 passes needed for optimal performance. Neither needle gauge nor the use of miniforceps, the use of suction or the type of sedation/anesthesia has been found to improve the diagnostic yield for lung cancer. The use of rapid on-site cytology examination does not increase the diagnostic yield. Molecular analysis (i.e. EGFR, KRAS and ALK) can be routinely performed on the majority of cytological samples obtained by EBUS-TBNA and conventional TBNA. There does not appear to be a superior method for specimen preparation (i.e. slide staining, cell blocks or core tissue). It is likely that optimal specimen preparation may vary between institutions depending on the expertise of pathology colleagues.
© 2014 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2014        PMID: 25377908     DOI: 10.1159/000368857

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  54 in total

Review 1.  Ultrasound techniques in the evaluation of the mediastinum, part I: endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) and transcutaneous mediastinal ultrasound (TMUS), introduction into ultrasound techniques.

Authors:  Christoph Frank Dietrich; Jouke Tabe Annema; Paul Clementsen; Xin Wu Cui; Mathias Maximilian Borst; Christian Jenssen
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

2.  Endobronchial Ultrasound-Guided Cautery-Assisted Transbronchial Forceps Biopsies: Safety and Sensitivity Relative to Transbronchial Needle Aspiration.

Authors:  Kyle Bramley; Margaret A Pisani; Terrence E Murphy; Katy L Araujo; Robert J Homer; Jonathan T Puchalski
Journal:  Ann Thorac Surg       Date:  2016-02-22       Impact factor: 4.330

3.  Reply: Is Endobronchial Ultrasound Influenced by Sedation Strategy? Comparing Apples to Apples.

Authors:  Roberto F Casal; Graciela Nogueras-González; Farrah Kheradmand
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

4.  Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario.

Authors:  C Lim; H S Sekhon; J C Cutz; D M Hwang; S Kamel-Reid; R F Carter; G da Cunha Santos; T Waddell; M Binnie; M Patel; N Paul; T Chung; A Brade; R El-Maraghi; C Sit; M S Tsao; N B Leighl
Journal:  Curr Oncol       Date:  2017-04-27       Impact factor: 3.677

5.  Comparison of multiple techniques for endobronchial ultrasound-transbronchial needle aspiration specimen preparation in a single institution experience.

Authors:  Nicola Rotolo; Maria Cattoni; Giorgio Crosta; Elisa Nardecchia; Albino Poli; Francesca Moretti; Valentina Conti; Stefano La Rosa; Lorenzo Dominioni; Andrea Imperatori
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 6.  Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)-from morphology to molecular testing.

Authors:  Luisella Righi; Francesca Franzi; Francesca Montarolo; Gaia Gatti; Massimo Bongiovanni; Fausto Sessa; Stefano La Rosa
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

Review 7.  International association for the study of lung cancer map, Wang lymph node map and rapid on-site evaluation in transbronchial needle aspiration.

Authors:  Qing-Hua Liu; Sixto Arias; Ko-Pen Wang
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 8.  Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis.

Authors:  Erik Folch; Daniel B Costa; Jeffrey Wright; Paul A VanderLaan
Journal:  Transl Lung Cancer Res       Date:  2015-08

9.  Utilization of ancillary studies in the cytologic diagnosis of respiratory lesions: The papanicolaou society of cytopathology consensus recommendations for respiratory cytology.

Authors:  Lester J Layfield; Sinchita Roy-Chowdhuri; Zubair Baloch; Hormoz Ehya; Kim Geisinger; Susan J Hsiao; Oscar Lin; Neal I Lindeman; Michael Roh; Fernando Schmitt; Nikoletta Sidiropoulos; Paul A VanderLaan
Journal:  Diagn Cytopathol       Date:  2016-08-26       Impact factor: 1.582

10.  Usefulness of conventional transbronchial needle aspiration in the diagnosis, staging and molecular characterization of pulmonary neoplasias by thin-prep based cytology: experience of a single oncological institute.

Authors:  Maria Teresa Ramieri; Ferdinando Marandino; Paolo Visca; Tommaso Salvitti; Enzo Gallo; Beatrice Casini; Francesca Romana Giordano; Claudia Frigieri; Mauro Caterino; Sandro Carlini; Massimo Rinaldi; Anna Ceribelli; Annarita Pennetti; Pier Luigi Alò; Mirella Marino; Edoardo Pescarmona; Massimo Filippetti
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.